Relmada Therapeutics Management
Management criteria checks 2/4
Relmada Therapeutics' CEO is Sergio Traversa, appointed in Apr 2012, has a tenure of 12.67 years. total yearly compensation is $4.78M, comprised of 14.7% salary and 85.3% bonuses, including company stock and options. directly owns 1.27% of the company’s shares, worth $139.36K. The average tenure of the management team and the board of directors is 4.9 years and 4.9 years respectively.
Key information
Sergio Traversa
Chief executive officer
US$4.8m
Total compensation
| CEO salary percentage | 14.7% |
| CEO tenure | 12.7yrs |
| CEO ownership | 1.3% |
| Management average tenure | 4.9yrs |
| Board average tenure | 4.9yrs |
Recent management updates
Recent updates
Relmada Therapeutics: Run Up Into Results May Resume Following This Drop
Mar 21Here's Why We're Watching Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation
Mar 13
Relmada: Phase 3 Data Did Not Live Up To Phase 2 Benchmark
Jan 14Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?
Dec 04Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?
Aug 29We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate
May 07We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate
Dec 15Relmada Downgraded at Truist, Guggenheim in wake of depression candidate failure
Oct 14Relmada Therapeutics: Initiating With A Strong BUY; Key Phase 3 Short-Term Catalysts Lined Up
Sep 14Relmada Therapeutics receives FDA fast track tag for REL-1017 to treat depression
Aug 09We're Hopeful That Relmada Therapeutics (NASDAQ:RLMD) Will Use Its Cash Wisely
Jul 14Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?
Feb 264 Clinical Catalysts On Tap For Relmada In 2022
Jan 28Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?
Nov 04Our First Look At Relmada Therapeutics
Jun 28We're Not Very Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate
Jun 28Here's Why We're Not Too Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation
Mar 09What Percentage Of Relmada Therapeutics, Inc. (NASDAQ:RLMD) Shares Do Insiders Own?
Jan 15
Enrollment underway in Relmada Therapeutics' late-stage depression study with REL-1017
Dec 07Relmada Therapeutics (RLMD) Investor Presentation - Slideshow
Dec 02Relmada Therapeutics (RLMD) Investor Presentation - Slideshow
Nov 16CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$86m |
| Jun 30 2024 | n/a | n/a | -US$87m |
| Mar 31 2024 | n/a | n/a | -US$94m |
| Dec 31 2023 | US$5m | US$701k | -US$99m |
| Sep 30 2023 | n/a | n/a | -US$112m |
| Jun 30 2023 | n/a | n/a | -US$129m |
| Mar 31 2023 | n/a | n/a | -US$144m |
| Dec 31 2022 | US$3m | US$668k | -US$157m |
| Sep 30 2022 | n/a | n/a | -US$153m |
| Jun 30 2022 | n/a | n/a | -US$157m |
| Mar 31 2022 | n/a | n/a | -US$143m |
| Dec 31 2021 | US$36m | US$630k | -US$126m |
| Sep 30 2021 | n/a | n/a | -US$112m |
| Jun 30 2021 | n/a | n/a | -US$86m |
| Mar 31 2021 | n/a | n/a | -US$71m |
| Dec 31 2020 | US$900k | US$600k | -US$59m |
| Sep 30 2020 | n/a | n/a | -US$43m |
| Jun 30 2020 | n/a | n/a | -US$30m |
| Mar 31 2020 | n/a | n/a | -US$23m |
| Dec 31 2019 | US$16m | US$214k | -US$15m |
| Sep 30 2019 | n/a | n/a | -US$18m |
| Jun 30 2019 | n/a | n/a | -US$17m |
| Mar 31 2019 | n/a | n/a | -US$17m |
| Dec 31 2018 | n/a | n/a | -US$17m |
| Sep 30 2018 | n/a | n/a | -US$11m |
| Jun 30 2018 | US$975k | US$376k | -US$9m |
Compensation vs Market: Sergio's total compensation ($USD4.78M) is above average for companies of similar size in the US market ($USD653.16K).
Compensation vs Earnings: Sergio's compensation has increased whilst the company is unprofitable.
CEO
Sergio Traversa (64 yo)
12.7yrs
Tenure
US$4,778,944
Compensation
Dr. Sergio Traversa, PharmD, MBA has been the Chief Executive Officer and a Director of Relmada Therapeutics, Inc. since April 18, 2012. Dr. Traversa served as Interim Chief Financial Officer at Relmada Th...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 12.7yrs | US$4.78m | 1.27% $ 139.4k | |
| Chief Financial Officer | 4.9yrs | US$2.34m | 0.29% $ 32.1k | |
| Chief Accounting & Compliance Officer | 4.9yrs | US$2.33m | 0.13% $ 14.1k | |
| Chief Scientific Officer | 4.2yrs | no data | no data | |
| VP & Head of Clinical Operations | 5.7yrs | no data | no data | |
| Chief Clinical Officer | 4.2yrs | no data | no data | |
| Head of Commercial | 2.4yrs | no data | no data | |
| Senior Clinical Development Advisor | no data | no data | no data | |
| Consultant | 7.7yrs | no data | no data |
4.9yrs
Average Tenure
63yo
Average Age
Experienced Management: RLMD's management team is considered experienced (4.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 12.7yrs | US$4.78m | 1.27% $ 139.4k | |
| Chief Financial Officer | 4.9yrs | US$2.34m | 0.29% $ 32.1k | |
| Independent Chairman of the Board | 9.4yrs | US$674.90k | 0% $ 0 | |
| Member of Scientific Advisory Board | 4.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 7.5yrs | no data | no data | |
| Independent Director | 1.9yrs | US$1.33m | 0% $ 0 | |
| Director | 9.1yrs | US$1.67m | 0.70% $ 77.0k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 5yrs | US$604.77k | no data | |
| Member of Scientific Advisory Board | 4.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.9yrs | no data | no data |
4.9yrs
Average Tenure
62.5yo
Average Age
Experienced Board: RLMD's board of directors are considered experienced (4.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 09:21 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Relmada Therapeutics, Inc. is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert LeBoyer | Aegis Capital Corporation |
| Maxim Jacobs | Edison Investment Research |
| Yatin Suneja | Guggenheim Securities, LLC |